Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRB | P09619 | 3/20 | 0.57 |
| ▸ | KDR | P35968 | 3/20 | 0.57 |
| ▸ | AURKA | O14965 | 1/20 | 0.57 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.57 |
| ▸ | JAK2 | O60674 | 1/20 | 0.57 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.57 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.57 |
| ▸ | PAK4 | O96013 | 1/20 | 0.57 |
| ▸ | ABL1 | P00519 | 1/20 | 0.57 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.57 |
| ▸ | LCK | P06239 | 1/20 | 0.57 |
| ▸ | FYN | P06241 | 1/20 | 0.57 |
| ▸ | CSF1R | P07333 | 1/20 | 0.57 |
| ▸ | RET | P07949 | 1/20 | 0.57 |
| ▸ | MET | P08581 | 1/20 | 0.57 |
| ▸ | PIM1 | P11309 | 1/20 | 0.57 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.57 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.57 |
| ▸ | PRKACA | P17612 | 1/20 | 0.57 |
| ▸ | FLT1 | P17948 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19300445 | 0.81 | ROCK1 (0.50) | JAK2JAK3PTK2ROCK1ALDH1A1 | |
| SCHEMBL5762378 | 0.80 | ROCK1 (0.50) | PDGFRBKDRAURKADAPK3JAK2 | |
| SCHEMBL6495201 | 0.79 | RXRA (0.45) | PDGFRBKDRAURKADAPK3JAK2 | |
| SCHEMBL1065564 | 0.74 | ROCK1 (0.57) | ROCK1 | |
| SCHEMBL6491751 | 0.74 | JUN (0.37) | PDGFRBKDRAURKADAPK3JAK2 | |
| SCHEMBL14214631 | 0.73 | KDR (0.84) | PDGFRBKDRAURKADAPK3JAK2 | |
| SCHEMBL3248536 | 0.72 | AURKA (0.49) | PDGFRBKDRAURKADAPK3JAK2 | |
| SCHEMBL16611976 | 0.70 | TUBB4A (0.52) | PDGFRBKDRAURKADAPK3JAK2 | |
| SCHEMBL17067809 | 0.69 | ALDH1A1 (0.53) | PDGFRBKDRALDH1A1KDM4ENPSR1 | |
| SCHEMBL7076191 | 0.68 | NUDT1 (0.55) | PDGFRBKDRAURKADAPK3JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6881737-B2 | Substituted triazinyl acrylamide derivatives and methods of use | AMGEN INC. (US) | 2005-04-19 | — | — | US | disclosed |
| US-6864255-B2 | Substituted triazinyl amide derivatives and methods of use | AMGEN INC. (US) | 2005-03-08 | — | — | US | disclosed |
| EP-1385833-A1 | TRIAZINYL AMIDE DERIVATIVES AS ANGIOGENESIS INHIBITORS | Amgen Inc. (US) | 2004-02-04 | — | — | EP | disclosed |
| US-20030139416-A1 | Substituted triazinyl acrylamide derivatives and methods of use | AMGEN INC. | 2003-07-24 | — | — | US | disclosed |
| US-20030087908-A1 | Substituted triazinyl amide derivatives and methods of use | AMGEN INC. | 2003-05-08 | — | — | US | disclosed |
| WO-2002083654-A1 | TRIAZINYL AMIDE DERIVATIVES AS ANGIOGENESIS INHIBITORS | AMGEN INC. (US) | 2002-10-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030139416-A1 | Substituted triazinyl acrylamide derivatives and methods of use | PKD1, PKD2, GLS | PDGFRB 652/4885KDR 1851/4885AURKA 1461/4885 |
| US-20030087908-A1 | Substituted triazinyl amide derivatives and methods of use | FLT4, FLT1, VEGFA | PDGFRB 26/4885KDR 4/4885AURKA 2141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.